Illinois News Desk

Delveinsight Business Research LLP

“Anemia In Chronic Kidney Disease (CKD) Pipeline Insight, 2023” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the Anemia In Chronic Kidney Disease Market. 

The Anemia In Chronic Kidney Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from pre-clinical developmental to marketed phases. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.

Anemia In Chronic Kidney Disease (CKD) Pipeline Analysis

The report provides insights into: 

• The report provides detailed insights into the emerging therapies for the treatment of Anemia In Chronic Kidney Disease and the aggregate therapies developed by major pharma companies.

• It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of clinical development.

• It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

• The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 

• It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the Anemia In Chronic Kidney Disease market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.  

Analysis of Emerging Therapies by Phases

The report covers the emerging products under different phases of clinical development like –

• Late stage products (Phase III)

• Mid-stage products (Phase II)

• Early-stage products (Phase I) 

• Pre-clinical and Discovery stage candidates

• Discontinued & Inactive candidates

Route of Administration

Anemia in Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

• Intra-articular

• Intraocular

• Intrathecal 

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

Molecule Type

Products have been categorized under various Molecule types, such as

• Oligonucleotide

• Peptide

• Small molecule

Learn How the Ongoing Clinical & Commercial Activities will Affect the Anemia In Chronic Kidney Disease Therapeutic Segment @

https://www.delveinsight.com/sample-request/anemia-in-chronic-kidney-disease-pipeline-insight

Anemia In Chronic Kidney Disease (CKD) Therapeutics Landscape

Traditional molecules for intravenous administration may cause rare but fatal anaphylactic reactions (especially for high molecular weight iron dextran), severe hypotension due to ‘labile’ iron (iron sucrose or iron gluconate) or need to be given at repeated small doses with a long infusion time to avoid toxicity (iron gluconate and iron sucrose). To further improve the treatment scenario, several key players, such as Akebia Therapeutics, GlaxoSmithKline, Kind Pharmaceuticals, and many others, are working on developing therapies for treating Anemia in Chronic Kidney Disease.

Currently, Biocad is leading the therapeutics market with its Anemia in Chronic Kidney Disease drug candidates in the most advanced stage of clinical development.

The Leading Players in the Anemia In Chronic Kidney Disease Therapeutics Market Include:

• Acceleron Pharma

• Biocad

• Celgene Corporation

• Chiasma

• Jiangsu HengRui Medicine

• Liminal BioSciences

• Shenyang Sunshine Pharmaceutical

• Xenetic Biosciences

And Many Others

Anemia in Chronic Kidney Disease Emerging and Marketed Drugs Co

• BCD-066: Biocad

• Daprodustat: GlaxoSmithKline

• EVRENZO: Astellas Pharma

• MIRCERA: Vifor Pharma

• SSS17: Shenyang Sunshine Pharmaceutical

• Vadadustat: Akebia Therapeutics

And Many More

Request the Sample PDF to Get a Better Understanding of the Emerging Drugs and Key Companies @

https://www.delveinsight.com/sample-request/anemia-in-chronic-kidney-disease-pipeline-insight

Latest Key Update in the Anemia In Chronic Kidney Disease Therapeutics Market 

On April 11, 2023, Genexine (KQ 095700, CEO Neil Warma) and its Asian regional partner, KG Bio, unveiled the interim results of the phase 3 clinical trial of GX-E4 (Efepoetin alfa), a candidate for CKD (Chronic Kidney Disease) induced anemia. Its non-inferiority results compared to Mircera (Methoxy Polyethylene Glycol-epoetin beta) were presented at the World Congress of Nephrology (WCN2023).

Table of Content (TOC)

1. Report Introduction

2. Executive Summary

3. Anemia In Chronic Kidney Disease Current Treatment Patterns

4. Anemia In Chronic Kidney Disease – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Anemia In Chronic Kidney Disease Late-Stage Products (Phase-III)

7. Anemia In Chronic Kidney Disease Mid-Stage Products (Phase-II)

8. Anemia In Chronic Kidney Disease Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Anemia In Chronic Kidney Disease Discontinued Products

13. Anemia In Chronic Kidney Disease Product Profiles

14. Key Companies in the Anemia In Chronic Kidney Disease Market

15. Key Products in the Anemia In Chronic Kidney Disease Therapeutics Segment

16. Dormant and Discontinued Products

17. Anemia In Chronic Kidney Disease Unmet Needs

18. Anemia In Chronic Kidney Disease Future Perspectives

19. Anemia In Chronic Kidney Disease Analyst Review  

20. Appendix

21. Report Methodology

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report:

https://www.delveinsight.com/sample-request/anemia-in-chronic-kidney-disease-pipeline-insight

Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management Strategies

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/